Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 31;13(1):e12158.
doi: 10.1002/dad2.12158. eCollection 2021.

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease

Jeffrey N Motter  1   2 , Xinhua Liu  3 , Min Qian  3 , Hannah R Cohen  1 , Davangere P Devanand  1   2
Affiliations

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease

Jeffrey N Motter et al. Alzheimers Dement (Amst). .

Abstract

Introduction: This study evaluated acute change in odor identification following atropine nasal spray challenge, and 8-week change in odor identification ability, as a predictor of long-term improvement in patients with mild to moderate Alzheimer's disease (AD) who received open-label cholinesterase inhibitor treatment.

Methods: In patients with clinical AD, the University of Pennsylvania Smell identification Test (UPSIT) was administered before and after an anticholinergic atropine nasal spray challenge. Patients were then treated with donepezil for 52 weeks.

Results: In 21 study participants, acute atropine-induced decrease in UPSIT was not associated with change in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) or Selective Reminding Test (SRT). Decline in odor identification performance from baseline to week 8 was indicative of a future decline in cognitive performance over 52 weeks.

Discussion: Change in odor identification with atropine challenge is not a useful predictor of treatment response to cholinesterase inhibitors. Short-term change in odor identification performance needs further investigation as a potential predictor of cognitive improvement with cholinesterase inhibitor treatment.

Keywords: Alzheimer's disease; acetylcholine; atropine; odor identification; olfaction.

PubMed Disclaimer

Conflict of interest statement

D. P. Devanand: Consultant to Eisai, Genentech, Axovant, Astellas, Acadia. Research support: NIA, DOD, Avanir.

References

    1. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. In: Jellinger K, Fazekas F, Windisch M, eds. Ageing and Dementia. Vienna: Springer Vienna; 1998:127‐140. - PubMed
    1. Davies P. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet North Am Ed. 1976;308:1403. - PubMed
    1. Doležal V, Kašparová J. Beta‐amyloid and cholinergic neurons. Neurochem Res. 2003;28:499‐506. - PubMed
    1. Hyman BT, Arriagada PV, Hoesen GWV. Pathologic changes in the olfactory system in aging and Alzheimer's Diseasea. Ann N Y Acad Sci. 1991;640:14‐19. - PubMed
    1. Li W, Howard JD, Gottfried JA. Disruption of odour quality coding in piriform cortex mediates olfactory deficits in Alzheimer's disease. Brain. 2010;133:2714‐2726. - PMC - PubMed

LinkOut - more resources